Prostate Stem Cells and Prostate Cancer

  1. D.A. LAWSON*,
  2. L. XIN*,
  3. R. LUKACS*,
  4. Q. XU*,
  5. D. CHENG, and
  6. O.N. WITTE*,,
  1. *Department of Microbiology, Immunology and Molecular Genetics,
  2. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine,
  3. Howard Hughes Medical Institute, University of California, Los Angeles, California 90095-1662

Abstract

Understanding prostate stem cells (PSCs) may provide insight for the design of therapeutics for prostate cancer. We have developeda quantitative in vivo colony-forming assay and have demonstrated that the Sca-1 antigen is present on the surfaceof a prostate cell subpopulation that possesses multiple stem cell properties. Immunofluorescent analysis demonstrates thatSca-1 is expressed by both basal and luminal cells in the proximal region of the adult prostate, but is not expressed by eitherlineage in more distal regions. The proximal region has been suggested as the PSC niche based on BrdU label-retention studiesand the presence of distinct smooth-muscle cells that produce high levels of TGF-β. Sca-1 is also expressed by nearly allcells within fetal prostate epithelial chords, suggesting Sca-1 may be conserved on PSCs throughout development. Malignantepithelial cells from TRAMP mice, as well as normal prostate cells with lentiviral-mediated alteration of the PTEN/AKT signalingpathway, give rise to PIN lesions and prostate cancer in vivo. Alteration of PTEN/AKT signaling in Sca-1-enrichedPSCs also results in PIN lesions, suggesting that PSCs can serve as one target for prostate carcinogenesis.

Footnotes

| Table of Contents